Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    for the treatment of hepatocellular carcinoma in previously treated patients. … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.

  2. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.

  3. Drug

    Zopiclone

    go.drugbank.com/drugs/DB01198
    ApprovedInvestigational

    Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. … In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

    Products: Nu-zopiclone, Nu-zopiclone Tablets - 7.5mg
  4. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD. … [A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola virus disease (EVD) in the Democratic Republic of Congo during a previous outbreak that began in 2018

  5. Drug

    Etomidate

    go.drugbank.com/drugs/DB00292
    ApprovedInvestigational

    Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.

    Products: ETOMIDATE-LIPURO 20MG/10ML INJ IN 10ML GA
  6. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  7. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.

    Products: HYLASE® DESSAU 150 IU, HYALASE POWDER FOR INJECTION 1500 iu/ampoule
  8. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733]

    Categories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia
  9. Drug

    Quinupramine

    go.drugbank.com/drugs/DB13246
    Approved

    Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant [A175003].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Non-Selective Monoamine Reuptake Inhibitors
  10. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. … L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.

    Products: LEUNASE FOR INJECTION 10,000 iu/vial, LEUNASE ENJEKTABL 10.000 IU FLAKON, 1 ADET